CK-MB mass test in ischemic myocardial injury. Comparison of two tests: Biomerieux Vidas and Sanofi Access immunoassays

The analytical and clinical performances of the new fluorescent immunoassay (CK‐MB mass Vidas‐BioMerieux) were examined and compared to the chemiluminescent test (CK‐MB mass Access‐Sanofi‐Pasteur). Assay precisions of the CK‐MB Vidas test within‐assay or between‐assay were less than 5.4 and 5.3%, respectively. Linearity was tested up to 214 μg/L. The CK‐MB Vidas test was free of interference with CK‐BB, CK‐MM, and macro‐CK. One hundred nineteen blood samples from patients with ischemic myocardial injury (IMI): acute myocardial infarction (AMI), suspected myocardial contusion (SMC), and unstable angina pectoris (UA), were tested using both immunoassays. In AMI, a good correlation was found (Y [CK‐MB Access] = 1.1372 × [CK‐MB Vidas] – 6.3902; r2 = 0.96). In UA and SMC, low values were observed and both methods were well correlated (Y [CK‐MB Access] = 1.3662 × [CK‐MB Vidas] + 0.0671; r2 = 0.97). Clinical data were in good agreement with both immunoassays. ROC analysis performed in AMI demonstrated that the clinical performances of the two assays were similar. J. Clin. Lab. Anal. 14:43–47, 2000. © 2000 Wiley‐Liss, Inc.